Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
See how your representatives voted on this bill.
DeepSyte matches this bill to the issues you care about and shows whether your reps' votes line up — not party, not press releases. Take the 2-minute values quiz to see your alignment.
Alignment with your views
Sign in and take the values quiz to see how this bill lines up with what you've said.
Summary
This bill reauthorizes the Accelerating Access to Critical Therapies for ALS Act through fiscal year 2031, extending its grant programs and regulatory initiatives for amyotrophic lateral sclerosis (ALS) research and therapy development. It adds requirements for the FDA to review clinical trial enrollment status during grant renewals and clarifies the definition of phase 3 clinical trials to include combined phase 2/3 trials. The bill also requires the FDA to publish an updated action plan within one year describing its five-year strategy for ALS and rare neurodegenerative disease initiatives, and mandates a Government Accountability Office report on the program's effectiveness.
Values analysis
Sign in and take the values quiz to get a personalized read on how this bill lines up with your positions.
How your representatives voted
Sign in to see how your representatives voted on this bill.